Inhibrx Biosciences publishes HexAgon-HN phase 2 results presentation
INBX•Inhibrx Biosciences published phase 2 results for ordastobart with pembrolizumab in recurrent or metastatic head-and-neck cancer. The combination’s confirmed response rate was 48.3%, versus 26.5% with pembrolizumab alone, while grade 3 or higher treatment-related adverse events occurred in 48.4%, versus 11.8%.
1. Phase 2 results
The combination achieved a 48.3% confirmed response rate, compared with 26.5% for pembrolizumab alone; six-month progression-free survival was 72.4% versus 42.8%. Among HPV-positive patients, confirmed response rates were 80% versus 33.3%, and six-month progression-free survival was 90% versus 33%. Grade 3 or higher treatment-related adverse events occurred in 48.4% of combination patients and 11.8% of those receiving pembrolizumab alone; treatment discontinuations were 35.5% and 14.7%, respectively.
2. Planned expansion
A 50-patient phase 2b expansion in HPV-positive oropharyngeal cancer with PD-L1 CPS ≥1 aims to support accelerated regulatory pathway discussions.
